Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Claire Harrison is Professor at Guy’s and St. Thomas’ Hospital in London. The focus of her work is to improve diagnosis, risk definition and therapy of myeloproliferative disorders (MPDs), for which she has a national and international reputation. Dr. Harrison is chief investigator of several trials, including COMFORTII - the first JAK inhibitor trial in Europe. In 2011, she took over as chair of the NCRI MPD group. Dr. Harrison works on translational work and clinical trials, and collaborates internationally with many centres including Addenbrooke’s, Mayo and Mount Sinai. She is a founder of MPN voice, is an advisory member for the MPN education foundation and colleaborates with MPN research foundation. She is also an advisor to Leukaemia Care and Bloodwise medical charities. Potential conflicts of interest include prior research funding from Novartis, Speakers and Advisory fees from Novartis, Shire, Gilead, Baxalta, CTI and Cellgene.